Form 4: Altimmune CMO Granted Significant Equity Awards

Altimmune's Chief Medical Officer, Christophe Arbet-Engels, was granted 450,000 stock options and 150,000 Restricted Stock Units.

Summary

• Christophe Arbet-Engels, Chief Medical Officer of Altimmune, Inc., received equity awards on October 1, 2025.
• The awards include 450,000 stock options with an exercise price of $3.87 per share.
• The stock options vest over four years, with 25% vesting on October 1, 2026, and the remainder in equal monthly installments over the subsequent 36 months.
• Additionally, 150,000 Restricted Stock Units (RSUs) were granted.
• The RSUs also vest over four years, with 25% vesting on October 1, 2026, and the remainder in equal annual installments over the subsequent three years.
• Vesting for both the stock options and RSUs is contingent upon Mr. Arbet-Engels' continued service to the company.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event, which is generally positive for executive retention and alignment but has a neutral impact on immediate company performance or outlook.

Positives

• The grant of significant equity awards to the Chief Medical Officer aligns executive incentives with long-term shareholder interests.
• The multi-year vesting schedule for both stock options and RSUs promotes the long-term retention of a key executive.

Negatives

• Potential for future dilution for existing shareholders upon the exercise of options and vesting of RSUs.

Future Outlook

The vesting schedules for the stock options and Restricted Stock Units extend over four years, indicating an expectation of continued service from the Chief Medical Officer through at least October 2029.

Industry Context

Granting stock options and Restricted Stock Units is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, aligning their interests with the long-term performance of the company.

Comparison to Industry Standards

• The structure of multi-year vesting for equity awards is standard practice across the biotech and broader corporate landscape, designed to encourage long-term executive retention and performance.
• Such compensation packages are typical for Chief Medical Officers in similar-sized biopharmaceutical companies, though specific comparable companies or projects are not detailed in this filing.

Stakeholder Impact

• Shareholders: Potential for future dilution when options are exercised and RSUs vest, but also benefits from enhanced executive alignment and retention.
• Management: Strengthens incentives for the Chief Medical Officer to drive long-term company performance.

Next Steps

• Vesting of stock options and Restricted Stock Units according to the specified schedules, contingent on continued service.

Key Dates

Keywords

Altimmune, ALT, Form 4, stock options, RSU, equity award, executive compensation, insider transaction